Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- Taisho Set for Delisting as Early as April after Tender Offer Completed
January 17, 2024
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Pfizer’s Ibrance Bags Label Update for Tamoxifen Combo in Breast Cancer
January 16, 2024
- Leqembi’s Anticipated EU Approval Delayed into April-June 2024: Eisai
January 15, 2024
- GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
- Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
- Daiichi Sankyo Healthcare to Launch Calonal OTC, Ayumi to Focus on Rx
January 12, 2024
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
- Japan Ethical Drug Sales Up 2.2% in November: Crecon
January 12, 2024
- Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit
January 11, 2024
- Maruho Nabs Japan Rights to AOBiome’s Eczema Drug
January 11, 2024
- New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
- FDA Rejects Astellas’ Gastric Cancer Med over Manufacturing Issues
January 10, 2024
- Shionogi, NTT Data to Build Distribution Platform for Digital Therapeutics
January 10, 2024
- Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds
January 10, 2024
- MTX Detoxifying Agent Megludase Finally Available in Japan
January 10, 2024
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…